PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time

被引：6
|
作者：
Quon, Harvey Charles
Ong, Aldrich
Cheung, Patrick
Chu, William
Chung, Hans T.
Vesprini, Danny
Chowdhury, Amit
Panjwani, Dilip
Pang, Geordi
Korol, Renee
Davidson, Melanie
Ravi, Ananth
McCurdy, Boyd
Zhang, Liying
Bucher, Oliver
Mamedov, Alexandre
Deabreu, Andrea
Lylyk, Elizabeth
Loblaw, Andrew
机构：
[1] CancerCare Manitoba, Winnipeg, MB, Canada
[2] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada
[3] BC Canc Agcy, Abbotsford, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).
    Phillips, Ryan
    Radwan, Noura
    Ross, Ashley
    Rowe, Steven P.
    Gorin, Michael A.
    Antonarakis, Emmanuel S.
    Deville, Curtiland
    Greco, Stephen C.
    Denmeade, Samuel R.
    Paller, Channing Judith
    Song, Daniel Y.
    Diehn, Maximilian
    Wang, Hao
    Carducci, Michael Anthony
    Pienta, Kenneth J.
    Pomper, Martin G.
    DeWeese, Theodore L.
    Dicker, Adam P.
    Eisenberger, Mario A.
    Tran, Phuoc T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
    Radwan, Noura
    Phillips, Ryan
    Ross, Ashley
    Rowe, Steven P.
    Gorin, Michael A.
    Antonarakis, Emmanuel S.
    Deville, Curtiland
    Greco, Stephen
    Denmeade, Samuel
    Paller, Channing
    Song, Daniel Y.
    Diehn, Maximilian
    Wang, Hao
    Carducci, Michael
    Pienta, Kenneth J.
    Pomper, Martin G.
    DeWeese, Theodore L.
    Dicker, Adam
    Eisenberger, Mario
    Tran, Phuoc T.
    BMC CANCER, 2017, 17
  • [23] A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
    Noura Radwan
    Ryan Phillips
    Ashley Ross
    Steven P. Rowe
    Michael A. Gorin
    Emmanuel S. Antonarakis
    Curtiland Deville
    Stephen Greco
    Samuel Denmeade
    Channing Paller
    Daniel Y. Song
    Maximilian Diehn
    Hao Wang
    Michael Carducci
    Kenneth J. Pienta
    Martin G. Pomper
    Theodore L. DeWeese
    Adam Dicker
    Mario Eisenberger
    Phuoc T. Tran
    BMC Cancer, 17
  • [24] Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
    C. Belliveau
    M. Barkati
    G. Delouya
    D. Taussky
    M. C. Beauchemin
    C. Lambert
    L. Beaulieu
    D. Beliveau-Nadeau
    B. Nicolas
    J. F. Carrier
    E. Vigneault
    C. Ménard
    Radiation Oncology, 17
  • [25] Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
    Belliveau, C.
    Barkati, M.
    Delouya, G.
    Taussky, D.
    Beauchemin, M. C.
    Lambert, C.
    Beaulieu, L.
    Beliveau-Nadeau, D.
    Nicolas, B.
    Carrier, J. F.
    Vigneault, E.
    Menard, C.
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [26] Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial
    Kishan, Amar U.
    Tyran, Marguerite
    Weng, Julius
    Upadhyaya, Shrinivasa
    Lamb, James
    Steinberg, Michael
    King, Christopher
    Cao, Minsong
    BRITISH JOURNAL OF RADIOLOGY, 2019, 92 (1099):
  • [27] Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy
    Sprave, Tanja
    Verma, Vivek
    Foerster, Robert
    Schlampp, Ingmar
    Bruckner, Thomas
    Bostel, Tilman
    Welte, Stefan Ezechiel
    Tonndorf-Martini, Eric
    Nicolay, Nils Henrik
    Debus, Juergen
    Rief, Harald
    RADIOTHERAPY AND ONCOLOGY, 2018, 128 (02) : 274 - 282
  • [28] Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
    Sundahl, Nora
    Vandekerkhove, Gillian
    Decaestecker, Karel
    Meireson, Annabel
    De Visschere, Pieter
    Fonteyne, Valerie
    Daan De Maeseneer
    Reynders, Dries
    Goetghebeur, Els
    Van Dorpe, Jo
    Verbeke, Sofie
    Annala, Matti
    Brochez, Lieve
    van der Eecken, Kim
    Wyatt, Alexander W.
    Rottey, Sylvie
    Ost, Piet
    EUROPEAN UROLOGY, 2019, 75 (05) : 707 - 711
  • [29] ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.
    Francolini, Giulio
    Di Cataldo, Vanessa
    Garlatti, Pietro
    Detti, Beatrice
    Caini, Saverio
    Bruni, Alessio
    Ingrosso, Gianluca
    D'Angelillo, Rolando Maria
    Alitto, Anna Rita
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Facchini, Gaetano
    Banini, Marco
    Simontacchi, Gabriele
    Desideri, Isacco
    Meattini, Icro
    Valicenti, Richard K.
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 132 - 132
  • [30] Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design
    Joanne M. van der Velden
    Helena M. Verkooijen
    Enrica Seravalli
    Jochem Hes
    A. Sophie Gerlich
    Nicolien Kasperts
    Wietse S. C. Eppinga
    Jorrit-Jan Verlaan
    Marco van Vulpen
    BMC Cancer, 16
12345